CD4 and hepatocellular carcinoma: In the case of T cells, although a study showed an increase of CD4+ and CD8+ T cell infiltration in murine models in other malignancies after treatment with sorafenib, a recent study reported that the infiltration of CD4+ and CD8+ T-cells remained constant in HCC models [58, 76].